HSK 31679
Alternative Names: HSK-31679Latest Information Update: 12 Aug 2024
At a glance
- Originator Haisco Pharmaceutical Group
- Class Antihyperlipidaemics; Antithrombotics
- Mechanism of Action Thyroid hormone receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hypercholesterolaemia; Non-alcoholic steatohepatitis
Most Recent Events
- 05 Jun 2024 Efficacy and adverse event data from a phase II trial in Hypercholesterolaemia presented at the European Association for the Study of the Liver Congress 2024 (EASL-2024)
- 01 Mar 2024 Haisco Pharmaceutical Group completes a phase II trial in Hypercholesterolaemia in China (PO) (NCT05795517)
- 05 Dec 2023 Haisco Pharmaceutical Group initiates a phase I pharmacokinetics trial (In Volunteers) in China (PO) (NCT06258746)